Crossmark

EP300 promotes hepatocellular carcinoma proliferation, migration and in vivo tumorigenicity revealed by integrated experimental and bioinformatic analyses

Crossref DOI link: https://doi.org/10.1186/s12967-026-07768-0

Published Online: 2026-02-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Zhipeng

Wang, Junbin

Wu, Xia

Shi, Hong

Ding, Youming

Liu, Xuejian
License Information

Text and Data Mining valid from 2026-02-04

Version of Record valid from 2026-03-06
More Information

Article History

Received: 28 October 2025

Accepted: 22 January 2026

First Online: 4 February 2026

Declarations

:

: The study involving human tissues and animal experiments complied with relevant guidelines and regulations. Human RT-qPCR validation on paired hepatocellular carcinoma (HCC) tumor and adjacent tissues was approved by the Institutional Review Board of The First Rehabilitation Hospital of Shandong Province (Approval No. DW2025001), and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki (2013). All animal procedures (subcutaneous xenografts in BALB/c nude mice) were approved by the Institutional Animal Care and Use Committee of The First Rehabilitation Hospital of Shandong Province (Approval No. DW2025001) and adhered to ARRIVE 2.0 guidelines.

: Not applicable. The manuscript does not include any individual person’s data (including images or videos) requiring consent for publication.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below